Cargando…

Neoadjuvant androgen suppression in patients treated with high-intensity focused ultrasound therapy

Detalles Bibliográficos
Autor principal:	Khochikar, Makarand V.
Formato:	Texto
Lenguaje:	English
Publicado:	Medknow Publications 2007
Materias:	Uroscan
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721509/ https://www.ncbi.nlm.nih.gov/pubmed/19675775

Ejemplares similares

Is incidence of prostate cancer higher in patients with end stage renal disease?
por: Khochikar, Makarand V.
Publicado: (2007)

Prostate cancer treatment does not increase the risk of cardiovascular events
por: Khochikar, Makarand V.
Publicado: (2007)

Relugolix – The novel oral androgen deprivation therapy for prostate cancer
por: Jena, Rahul
Publicado: (2020)

HERO trial: A rescue from injectable androgen deprivation therapy
por: Ranjan, Satish Kumar
Publicado: (2021)

Survival following primary androgen deprivation therapy among men with localized prostate cancer
por: Vasudeva, Pawan, et al.
Publicado: (2008)

Comparing outcomes between neoadjuvant hormonal therapy followed by prostatectomy versus upfront prostatectomy in high-risk prostate cancer: The road ahead
por: Bhargava, Priyank
Publicado: (2023)

ARASENS Trial: Should darolutamide now be added to androgen-deprivation therapy and docetaxel in patients with metastatic, hormone-sensitive prostate cancer?
por: Kumar, Naveen
Publicado: (2022)

What happens to the patients with muscle-invasive bladder cancer who refuse cystectomy after neoadjuvant chemotherapy?
por: Maheshwari, Ruchir, et al.
Publicado: (2009)

Can suppressive antibiotics be avoided in the postnatal management of antenatally detected obstructive hydronephrosis?
por: Reddy, Sreedhar V., et al.
Publicado: (2007)

TITAN trial; shifting focus from hormone-refractory to hormone-sensitive prostate cancer
por: Kumar, Gautam
Publicado: (2020)

Comparison of multiparametric ultrasound versus multiparametric magnetic resonance imaging for diagnosis of carcinoma prostate: The CADMUS trial
por: Tarigopula, Vivek
Publicado: (2022)

Botulinum toxin in high-risk BPH patients in retention
por: Reddy, Sreedhar, et al.
Publicado: (2008)

T1 bladder cancer on restaging transurethral resection should be treated with immediate cystectomy
por: Gautam, Gagan, et al.
Publicado: (2007)

Benefit of cabazitaxel in previously treated metastatic castration-resistant prostate cancer; CARD trial
por: Mishra, Ankit
Publicado: (2020)

Pembrolizumab in bacillus Calmette-Guérin unresponsive nonmuscle-invasive bladder cancer; a difficult to treat disease (KEYNOTE-057)
por: Kumar, Bhuwan
Publicado: (2021)

Search for new α1a-adrenoceptor-selective antagonist for treating lower urinary tract symptoms associated with benign prostatic hyperplasia
por: Khurana, Naval, et al.
Publicado: (2007)

Can early salvage radiotherapy replace adjuvant radiotherapy as the new standard of care for high-risk postradical prostatectomy patients?
por: Pandey, Abhishek
Publicado: (2021)

Apalutamide: A novel therapy for non metastatic castration-resistant carcinoma prostate
por: Jayasimha, Sudhindra
Publicado: (2018)

Triple therapy for metastatic castration sensitive prostate cancer: PEACE-1 trial
por: Singh, Kirti
Publicado: (2022)

Role of atezolizumab therapy combined with platinum-based chemotherapy in untreated metastatic urothelial carcinoma – The new landscapes (IMvigor130 trial)
por: Misra, Ankit
Publicado: (2021)

Approach to chemotherapy for high-risk, stage 1, non-seminomatous, germ cell testicular tumors
por: Anand, Madhur
Publicado: (2021)

Checkmate 274 trial: Is Nivolumab the new standard in adjuvant setting for high-risk muscle invasive urothelial carcinoma?
por: Kumar, Naveen
Publicado: (2021)

LATITUDE: A landmark trial for high-risk metastatic castration-sensitive prostate cancer: Final overall survival analysis
por: Kumar, Gautam
Publicado: (2020)

Safety and efficacy of active surveillance in patients with localized prostate cancer
por: Mavuduru, Ravimohan, et al.
Publicado: (2008)

Renal and testicular involvement in COVID-19 patients – implication for the urologist
por: Pandey, Abhisek
Publicado: (2020)

A novel approach to management of nocturia in patients with benign prostatic hyperplasia
por: Sengottayan, Vengetesh K., et al.
Publicado: (2009)

Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
por: Talwar, Harkirat Singh
Publicado: (2021)

Endocrine treatment in advanced prostate cancer: When to start?
por: Choudhrie, A. V., et al.
Publicado: (2009)

Malignant ureteral obstruction: Whether decompression really improves patient outcomes and quality of life?
por: Muruganandham, K., et al.
Publicado: (2008)

Intraprostatic injection of botulinum toxin A: A promising treatment for patients with benign prostatic hyperplasia
por: Agrawal, S. K., et al.
Publicado: (2009)

The role of 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: Is it the new beginning
por: Agrawal, Sumit
Publicado: (2020)

Prognostic stratification of renal cell carcinoma using a pathological triad of microvascular invasion, Fuhrman's grade and tumor size
por: Prakash, Gagan, et al.
Publicado: (2007)

Stress urinary incontinence: Sling or colposuspension?
por: Mukha, Rajiv Paul, et al.
Publicado: (2007)

A comparison of traditional anterior colporrhaphy, polypropylene mesh and porcine dermis in cystocele repair
por: Singh, Pratipal, et al.
Publicado: (2007)

Is there a better indicator for predicting the outcome of trial without catheter?
por: Shanmugasundaram, R., et al.
Publicado: (2007)

Relevance of inflammatory pseudotumor associated with bladder tumor
por: Kurien, Annamma, et al.
Publicado: (2007)

Should small renal masses be managed expectantly?
por: Singla, Manish, et al.
Publicado: (2007)

Temsirolimus, interferon alfa or both in advanced renal-cell carcinoma: One plus one does not always equal two
por: Grover, S., et al.
Publicado: (2007)

Can Reflex UroVysion fluorescence in situ hybridization predict tumor recurrence during follow-up?
por: Kurien, Annamma, et al.
Publicado: (2007)

Does dutasteride reduce perioperative blood loss and postoperative complications after transurethral resection of the prostate?
por: Shanmugasundaram, R., et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_5af0lj4bg0tps80i6on1kf46r1